Related Party Transactions	12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 — RELATED PARTY TRANSACTIONS Takeda Agreements In connection with the Takeda Stock Purchase Agreement described in Note 3 “Research and Development Collaboration Agreements”, Takeda became a related party, following the stock purchase. Refer to Note 3, Research and Development Collaboration Agreements, for more details about the Takeda Collaboration Agreement, the Takeda Multi-Target Agreement and the Takeda Development and License Agreement. Refer to Note 12, “Stockholders’ Equity”, for more detail about the Takeda Stock Purchase Agreement. Jonathan Lanfear, a director of the Company, was the Vice President and Global Head of Oncology and Neuroscience Business Development for Takeda until September 25, 2020. Public Offerings On September 25, 2018, the Company closed its underwritten public offering (the “2018 Public Offering”) of its common stock, in which Longitude Venture Partners III, L.P. and CDK Associates, L.L.C., current stockholders of the Company, purchased 365,000 and 545,454 shares of common stock, respectively, at the public offering price. Scott Morenstein, a director of the Company is a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., David Hirsch, a director of the Company, is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P. On November 25, 2019, the Company closed its underwritten public offering (the “2019 Public Offering”) of its common stock and 250 shares of our newly designated Series A Convertible Preferred Stock, in which Longitude Venture Partners III, L.P. and CDK Associates, L.L.C., purchased 937,500 and 468,750 shares of common stock, respectively, at the public offering price.

Related Party Transactions

12 Months Ended

Dec. 31, 2020

NOTE 7 — RELATED PARTY TRANSACTIONS

Takeda Agreements

In connection with the Takeda Stock Purchase Agreement described in Note 3 “Research and Development Collaboration Agreements”, Takeda became a related party, following the stock purchase. Refer to Note 3, Research and Development Collaboration Agreements, for more details about the Takeda Collaboration Agreement, the Takeda Multi-Target Agreement and the Takeda Development and License Agreement. Refer to Note 12, “Stockholders’ Equity”, for more detail about the Takeda Stock Purchase Agreement. Jonathan Lanfear, a director of the Company, was the Vice President and Global Head of Oncology and Neuroscience Business Development for Takeda until September 25, 2020.

Public Offerings

On September 25, 2018, the Company closed its underwritten public offering (the “2018 Public Offering”) of its common stock, in which Longitude Venture Partners III, L.P. and CDK Associates, L.L.C., current stockholders of the Company, purchased 365,000 and 545,454 shares of common stock, respectively, at the public offering price. Scott Morenstein, a director of the Company is a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., David Hirsch, a director of the Company, is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P.

On November 25, 2019, the Company closed its underwritten public offering (the “2019 Public Offering”) of its common stock and 250 shares of our newly designated Series A Convertible Preferred Stock, in which Longitude Venture Partners III, L.P. and CDK Associates, L.L.C., purchased 937,500 and 468,750 shares of common stock, respectively, at the public offering price.